Search
Virginia Paid Clinical Trials
A listing of 1837 clinical trials in Virginia actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
481 - 492 of 1837
Virginia is currently home to 1837 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study of Low-intensity Focused Ultrasound Effects on Heat Evoked fMRI Signals
Recruiting
Study aims to examine the effects of noninvasive brain stimulation on brain signals. This insight may have potential clinical implications for addiction, pain, and mental health populations. Participants will receive MRI and CT imaging. Participants receive low-intensity focused ultrasound (LIFU) to temporarily change brain activity. Participants then receive fMRI scans to measure changes in both resting and heat evoked brain signaling using a quantitative sensory testing device. Heart rate, blo... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/03/2025
Locations: Fralin Biomedical Research Institute, Roanoke, Virginia
Conditions: Pain
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
Recruiting
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia
Conditions: Non-Small Cell Lung Cancer
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: MS Center of Greater Washington, P.C., Vienna, Virginia
Conditions: Relapsing Multiple Sclerosis
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Recruiting
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/03/2025
Locations: Sentara Neuroscience Institute, Virginia Beach, Virginia
Conditions: Relapsing-Remitting Multiple Sclerosis
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Recruiting
Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
06/03/2025
Locations: Octapharma Research Site, Charlottesville, Virginia
Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
Cardiogenic Shock Working Group Registry
Recruiting
The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Inova Health System, Falls Church, Virginia
Conditions: Cardiogenic Shock
A Study of ZL-1310 in Participants With Selected Solid Tumors
Recruiting
A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Zai Lab Site 2006, Fairfax, Virginia
Conditions: Solid Tumors
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Recruiting
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/02/2025
Locations: Atea Study Site, Chesapeake, Virginia
Conditions: HEPATITIS C VIRUS CHRONIC INFECTION
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Recruiting
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.
The main goals of this study are to:
* Evaluate the efficacy of BMS-986489 vs durvalumab
* Evaluate the safety profile of BMS-986489
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Limited Stage Small Cell Lung Cancer
Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder
Recruiting
Premenstrual dysphoric disorder (PMDD) is a severe affective disorder impacting millions of women worldwide, thought to be due to altered sensitivity to hormone fluctuations across the menstrual cycle. Neuroactive steroid hormones (NAS) and the gamma-aminobutyric acid (GABA)-A receptor (GABAAR) are thought to play a role in PMDD. This research will assess the blood levels of GABAergic NAS, expression of associated enzymes, and expression of GABAAR subunits across the premenstrual (luteal) phase... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
06/02/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Premenstrual Dysphoric Disorder (PMDD)
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Recruiting
This phase 3 study will be conducted in different countries all over the world.
The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer.
Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemothe... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: USOR - Virginia Oncology Associates - Norfolk, Norfolk, Virginia
Conditions: Platinum-resistant Ovarian Cancer
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Recruiting
This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation